Co-Diagnostics Q3 2024 Earnings Preview
| CODX Stock | USD 1.01 0.05 4.72% |
Slightly above 61% of Co Diagnostics' investor base is looking to short. The analysis of overall sentiment of trading Co Diagnostics stock suggests that many investors are alarmed at this time. Co Diagnostics' investing sentiment can be driven by a variety of factors including economic data, Co Diagnostics' earnings reports, geopolitical events, and overall market trends.
CODX |
Co-Diagnostics is set to announce Q3 earnings with consensus EPS estimate of -0.33 and revenue estimate of 0.38M.
Read at seekingalpha.com
 |
Co Diagnostics Fundamental Analysis
We analyze Co Diagnostics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Co Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Co Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Co Diagnostics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Co Diagnostics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Co Diagnostics stock to make a market-neutral strategy. Peer analysis of Co Diagnostics could also be used in its relative valuation, which is a method of valuing Co Diagnostics by comparing valuation metrics with similar companies.
Peers
Co Diagnostics Related Equities
| NAOV | NanoVibronix | 9.23 | ||||
| VVOS | Vivos Therapeutics | 8.47 | ||||
| MOVE | Movano | 8.18 | ||||
| NPCE | Neuropace | 7.78 | ||||
| CLPT | Clearpoint Neuro | 6.76 | ||||
| SENS | Senseonics Holdings | 6.67 | ||||
| TIVC | Tivic Health | 4.17 | ||||
| RPID | Rapid Micro | 3.60 | ||||
| NVNO | EnVVeno Medical | 3.33 | ||||
| NURO | NeuroMetrix | 2.41 | ||||
| HSCS | Heart Test | 1.91 | ||||
| INGN | Inogen | 1.85 | ||||
| BBLG | Bone Biologics | 1.63 | ||||
| IINN | Inspira Technologies | 0.74 | ||||
| BJDX | Bluejay Diagnostics | 0.57 | ||||
| CVRX | CVRx | 0.54 | ||||
| SRDX | SurModics | 0.36 | ||||
| RSLS | ReShape Lifesciences | 0.54 | ||||
| BMRA | Biomerica | 3.13 |
Additional Tools for CODX Stock Analysis
When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.